Stay updated with breaking news from Arcus Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities analysts expect Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) to announce $163.47 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Arcus Biosciences’ earnings, with the highest sales estimate coming in at $444.90 million and the lowest estimate coming in at $22.50 million. Arcus Biosciences reported sales of […]
Arcus Biosciences (NYSE:RCUS – Get Rating)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a report issued on Friday, Zacks.com reports. Cantor Fitzgerald also issued estimates for Arcus Biosciences’ FY2022 earnings at ($3.32) EPS and FY2022 earnings at ($4.22) EPS. RCUS has been the subject of a number of other […]
The current chemotherapy-dominated landscape of cervical cancer treatment is set to change to include multiple different drug classes. ...
Feb 2, 2021 10:50am Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi Biosciences’ PD-1 inhibitor toripalimab. (Kritchanut/iStock/Getty Images Plus/Getty Images) On the heels of Novartis licensing BeiGene’s tislelizumab, another China-made PD-1 inhibitor has found itself a new U.S. collaborator in a company that’s just pivoting to immuno-oncology. Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi Biosciences’ anti-PD-1 antibody toripalimab, which was first approved in China for previously treat...